[Progress and Discussion of Perioperative Targeted Therapy in Patients 
with EGFR-mutated Resectable Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Pharmacology

Background:

• Lung cancer remains a leading global cause of cancer mortality.
• Non-small cell lung cancer (NSCLC) constitutes approximately 80% of all lung cancer cases.
• A significant portion of NSCLC patients (around 30%) present with resectable early to middle-stage disease.

Purpose of the Study:

• To review the clinical progress of perioperative adjuvant targeted therapy for resectable NSCLC with EGFR mutations.
• To discuss critical issues and challenges in ongoing clinical research for this therapeutic approach.

Main Methods:

• Literature review of clinical research on perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC.
• Analysis of recent advancements and guideline recommendations for EGFR-TKIs in adjuvant settings.

Main Results:

• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have emerged as a significant breakthrough in adjuvant targeted therapy for EGFR-mutated resectable NSCLC.
• Current guidelines recommend the clinical use of EGFR-TKIs for this specific patient population.

Conclusions:

• Perioperative adjuvant targeted therapy with EGFR-TKIs represents a promising strategy for improving outcomes in EGFR-mutated resectable NSCLC.
• Further research is needed to address key clinical questions and optimize treatment protocols.